Related Experiment Video
Updated: Jan 1, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
Małgorzata Ostrowska1, Jacek Kubica1, Piotr Adamski1
1Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Insights
Optimizing antiplatelet therapy after coronary interventions is crucial. Platelet function testing can guide de-escalation of P2Y12 inhibitors to reduce bleeding risks while maintaining efficacy.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- P2Y12 receptor inhibitors are essential post-percutaneous coronary interventions.
- High on-treatment platelet reactivity (HTPR) with clopidogrel necessitates potent alternatives.
- More potent inhibitors increase bleeding risk due to low on-treatment platelet reactivity (LTPR).
Purpose of the Study:
- To review diagnostic tools for optimizing antiplatelet therapy.
- To focus on de-escalating therapy to minimize bleeding complications.
- To discuss future perspectives in personalized antiplatelet treatment.
Main Methods:
- Review of current literature on P2Y12 inhibitors and platelet function testing.
- Analysis of the balance between platelet inhibition and bleeding risk.
- Exploration of individualized antiplatelet therapy strategies.
Main Results:
- Potent P2Y12 inhibitors (prasugrel, ticagrelor, cangrelor) address HTPR but increase bleeding risk (LTPR).
- Individualized therapy is needed to balance efficacy and safety.
- Platelet function testing offers a way to guide treatment adjustments.
Conclusions:
- Personalized antiplatelet therapy is essential for patients undergoing percutaneous coronary interventions.
- Platelet function testing plays a key role in optimizing P2Y12 inhibitor selection and de-escalation.
- Future strategies should focus on reducing bleeding events through tailored antiplatelet approaches.
Abstract:
Antiplatelet therapy with P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) is a cornerstone of medical therapy after percutaneous coronary interventions. Significant prevalence of high on-treatment platelet reactivity (HTPR) on clopidogrel treatment led to introduction of more potent P2Y12 inhibitors: prasugrel (a third generation thienopyridine), ticagrelor, and cangrelor (cyclopentyl-triazolo-pyrimidines). Nevertheless, more potent platelet inhibition and resulting low on-treatment platelet reactivity (LTPR) has led to increased risk of major bleeding events. These limitations resulted in a need for an individualized antiplatelet therapy approach. This review discusses the current role and future perspectives of diagnostic tools such as platelet function testing to optimize antiplatelet therapy with a focus on deescalating therapies to reduce bleeding risks.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management